October 15, 2026 – Gastroesophageal reflux disease (GERD) remains one of the most pervasive gastrointestinal conditions in the United States, affecting nearly one in five adults. While proton pump inhibitors (PPIs) have served as the cornerstone of treatment for decades, a significant subset of patients continues to struggle with persistent symptoms. New clinical data unveiled at the American College of Gastroenterology (ACG) annual meeting in Nashville, Tennessee, suggests a shift in the therapeutic landscape: the potassium-competitive acid blocker (P-CAB) tegoprazan has demonstrated significant efficacy in treating non-erosive reflux disease (NERD), the most common phenotype of the condition.
The Challenge of NERD and the Limitations of Current Therapy
For the millions of Americans living with chronic heartburn and regurgitation, the diagnostic classification of their condition is critical. NERD, which accounts for approximately 70% of all GERD cases, is characterized by bothersome reflux symptoms in the absence of visible esophageal mucosal breaks during an endoscopy.
Despite its high prevalence, NERD has historically been difficult to manage. Dr. Ronnie Fass of the Case Western Reserve University School of Medicine, who presented the findings of the Phase III TRIUMpH-NERD trial, noted that approximately 35% of all GERD patients report dissatisfaction with existing PPI-based regimens. "If you look at NERD patients, symptom relief with standard-dose PPIs has been reported to be around 50%," Fass explained.
The limitations of PPIs often stem from their pharmacokinetic and pharmacodynamic profiles. They require time to reach steady-state acid inhibition and must be taken under specific conditions—often before meals—to maximize efficacy. Tegoprazan, a novel P-CAB, offers a distinct departure from this model. Its unique chemical structure allows for rapid onset of action, capable of raising gastric pH above 4 within 45 minutes of administration. Furthermore, it achieves a steady state within a single day, providing consistent acid control without the fluctuations often seen with traditional therapies.
Chronology of the TRIUMpH-NERD Trial
The development of tegoprazan as a front-line treatment has been a rigorous, multi-year process culminating in the expansive TRIUMpH-NERD study.
- Trial Initiation: The double-blind, multi-center study (NCT05587322) was launched across 91 sites in the United States to evaluate the safety and efficacy of two dosages of tegoprazan (50 mg and 100 mg) against a placebo.
- Patient Selection: The study enrolled 783 participants, with a mean age ranging from 51 to 53. The demographic breakdown included a diverse patient population (65-74% women; 68-74% white; 22-27% Black). A critical inclusion criterion was that all patients must have reported heartburn symptoms for at least six months and maintained a normal endoscopy during the screening period.
- Baseline Status: At the start of the study, the baseline health of participants was striking: only 6.2% of the enrolled patients reported having any 24-hour heartburn-free days, underscoring the chronic and debilitating nature of their condition.
- Initial Findings (Week 4): By the fourth week of the trial, the treatment groups demonstrated a statistically significant divergence from the placebo group, with clear dose-dependent improvements.
- Extension Period: Following the initial four-week phase, a 20-week extension period allowed researchers to assess the durability of the treatment, yielding promising long-term data for patients suffering from chronic reflux.
Supporting Data: Efficacy and Symptom Management
The primary endpoint of the TRIUMpH-NERD trial was the percentage of 24-hour heartburn-free days through week 4. The results were compelling: patients randomized to the placebo, 50-mg tegoprazan, and 100-mg tegoprazan groups reported mean percentages of heartburn-free days at 17.3%, 26.2%, and 30.1%, respectively.
When analyzed for relative improvement, tegoprazan 50 mg outperformed the placebo by 51% (P=0.0006), while the 100-mg dose showed a 74% improvement (P<0.0001). These data points were bolstered by significant secondary endpoints, including the percentage of days without daytime and nighttime heartburn.
Perhaps most significant to patient quality of life was the exploratory endpoint regarding regurgitation. Regurgitation is frequently cited by patients as the most distressing symptom of GERD. The trial revealed that both doses of tegoprazan significantly reduced regurgitation, with 31.9% of the 50-mg group and 33.8% of the 100-mg group reporting symptom-free days, compared to just 23.6% in the placebo group (P=0.0012 and P<0.0001, respectively).
By the conclusion of the 20-week extension period, the sustained efficacy was evident: 47.8% of patients in the 50-mg arm and 50.4% in the 100-mg arm remained heartburn-free over a 24-hour cycle. Furthermore, the severity of both heartburn and regurgitation was significantly lower in the treatment arms compared to the placebo, confirming that the drug not only reduces frequency but also attenuates the intensity of reflux episodes.
Professional Discourse and Official Responses
The presentation at the ACG meeting triggered a robust discussion regarding the study’s design and the observed placebo effect. During the Q&A session, Dr. Henry Parkman of the Lewis Katz School of Medicine at Temple University raised a pertinent question regarding the improvement noted in the placebo arm.
"Were any additional things being done at the time of enrollment, like diet management… that might have led to the decreased heartburn and regurgitation in patients on placebo?" Parkman asked.
Dr. Fass acknowledged that while lifestyle modifications—such as dietary adjustments—are often adopted by patients entering clinical trials, the placebo effect is a well-documented phenomenon in gastrointestinal research. "The good thing is that we were able to show that there was still a big separation between the treatment arms and placebo," Fass noted. The statistical significance maintained despite the placebo response serves as a testament to the pharmacological potency of tegoprazan.
Safety profiles also remained favorable throughout the study. Rates of serious treatment-emergent adverse events (TEAEs) were comparable across all three groups. Discontinuation due to adverse events was low, occurring in 1.1% of the placebo group, 1.9% of the 50-mg group, and 1.5% of the 100-mg group, suggesting that tegoprazan is well-tolerated for long-term use.
Clinical Implications and Future Outlook
The implications of these findings are substantial. For clinicians, the availability of a fast-acting, reliable P-CAB represents a new tool in the gastroenterologist’s arsenal. Because tegoprazan acts differently than PPIs—specifically regarding its binding properties and its ability to maintain gastrin levels within the normal range—it may become the preferred option for patients who have failed to achieve adequate relief with standard acid-suppression therapies.
The momentum behind tegoprazan is already building in the regulatory sphere. In January 2026, a new drug application (NDA) for tegoprazan was submitted to the U.S. Food and Drug Administration (FDA) for the treatment of GERD. Should the FDA grant approval, the drug would provide a much-needed alternative for the millions of Americans currently living with suboptimal symptom control.
As the medical community looks toward the next phase of implementation, the focus will likely shift to real-world evidence and cost-effectiveness comparisons. However, based on the data presented at the ACG meeting, tegoprazan appears poised to redefine the standard of care for non-erosive reflux disease, offering a faster, more consistent path to relief for patients who have spent years navigating the limitations of conventional medicine.
